Cellular Repair & Recovery
KPV
Lys-Pro-Val tripeptide
KPV (Lys-Pro-Val, α-MSH 11-13)
Research context
KPV represents the three C-terminal residues of α-melanocyte-stimulating hormone. Research focuses on NF-κB pathway modulation in epithelial cell lines and on transport via the PepT1 oligopeptide transporter, with cytokine transcript quantification in intestinal epithelial models.
Common assays: NF-κB reporter assay · Cytokine transcript quantification · PepT1 transport
Specification
| Designation | Lys-Pro-Val tripeptide |
|---|---|
| Full name | KPV (Lys-Pro-Val, α-MSH 11-13) |
| Sequence | Lys-Pro-Val |
| CAS number | 67247-12-5 |
| Molecular formula | C16H30N4O4 |
| Molecular weight | 342.44 g/mol |
| Formats | 10 mL Vial · 15 mL Advanced Liquid Peptide Spray |
| Solubility | Sterile water, bacteriostatic water |
| Storage | Lyophilised: −20 °C, desiccated. Reconstituted: 2–8 °C. |
| Regulatory status | Not an approved drug. Removed from FDA 503A Category 2 in April 2026 and recommended for the 503A bulks list by the advisory committee in July 2026. Since 30 October 2026, an HHS interim policy says the agency will not take enforcement action against licensed 503A compounding of it under set conditions. It has not been added to the bulks list. 2026 status by compound → |
| Current lot | KPV10VCS0126 → |
KPV COA: certificates of analysis by lot
2 lots of KPV have a published certificate of analysis from AxisPharm, LLC, an independent laboratory. Each certificate reports the laboratory's results for that lot.
| Lot | Format | Purity (HPLC-UV) | Reported |
|---|---|---|---|
| KPV10VCS0126 | 10 mg Vial | >99.3% | 2026-02-20 |
| KPV10N1125 | 10 mg Spray | >99.0% | 2025-11-24 |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al.PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationGastroenterology · 2008 Find on PubMed ↗
- Brzoska T, Luger TA, Maaser C, et al.Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivoEndocrine Reviews · 2008 Find on PubMed ↗
Common questions
What is KPV derived from?
The final three residues (lysine, proline, valine) of α-melanocyte-stimulating hormone, a 13-residue endogenous peptide.
What pathway does the KPV literature focus on?
Predominantly NF-κB signalling, with pro-inflammatory cytokine transcript levels as the usual measured endpoint in epithelial models.
Where can I see the KPV certificate of analysis?
Every published KPV lot has its own certificate page on this site, listed under "KPV COA" above. There are 2 published lots; the most recent, lot KPV10VCS0126, was reported on 2026-02-20 at >99.3% purity by HPLC-UV. The certificates are issued by AxisPharm, LLC, an independent laboratory.
Components, blends and pathway
Related compounds
KLOW
BPC-157 / TB-500 / GHK-Cu / KPV
A prepared four-component blend combining repair-signalling and cytokine-pathway compounds.
GHK-Cu / KPV
Peptide blend
A prepared blend combining a copper tripeptide with the α-MSH C-terminal fragment.
Wolverine Oral
BPC-157 / KPV
A prepared capsule blend combining BPC-157 with the α-MSH C-terminal tripeptide.
Thymosin Alpha-1 / KPV
Peptide blend
A prepared blend combining a thymic peptide with the α-MSH C-terminal tripeptide.